Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Melissa D. Hall"'
Autor:
Paul V. Suhocki, Meghana Konanur, Tzu-Hao Lee, James Ronald, Tony P. Smith, Waleska M. Pabon-Ramos, Charles Y. Kim, D. Lewis, Cole Ziegler, Melissa D. Hall, Steven S Choi
Publikováno v:
Journal of Vascular and Interventional Radiology. 30:163-169
PURPOSE To determine whether proton pump inhibitor (PPI) use increases the rate of new or worsening hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) creation. MATERIALS AND METHODS In this retrospective study, 28
Autor:
Anastasia Ivanova, Beverly S. Mitchell, Marie Green, Anandhi R. Johri, Peter M. Voorhees, Hendrik W. van Deventer, Elizabeth G. Trehu, Dixie Lee Esseltine, Reynaldo Garcia, Fred J. Kudrik, Thomas C. Shea, Julian Adams, Don A. Gabriel, Celeste Lindley, Paul Jones, Melissa D. Hall, E. Claire Dees, Mary Jo Lehman, Robert Z. Orlowski, Tammy Allred, Susan Natoli, Jason M. Collins
Publikováno v:
Blood. 105:3058-3065
Proteasome inhibitors, a novel class of chemotherapeutic agents, enhance the antitumor efficacy of anthracyclines in vitro and in vivo. We therefore sought to determine the maximum tolerated dose (MTD) and dose-limiting toxicities of bortezomib and p
Autor:
Melissa D Hall
Publikováno v:
Oncology Nursing Forum. 30:551-555
Autor:
Melissa D, Hall
Publikováno v:
Oncology nursing forum. 30(4)
Autor:
Melissa D. Hall, Julie Koehler, Thomas C. Shea, Cherie H. Dunphy, Beverly S. Mitchell, Robert Z. Orlowski, Cathe Hogan, Lee R. Berkowitz, Hendrik W. van Deventer
Publikováno v:
American journal of hematology. 71(3)
We studied 28 patients with accelerated phase chronic myelogenous leukemia (CML) who were enrolled on the Novartis expanded access study 114. Diagnosis of accelerated phase CML was based on karyotypic evolution (n = 9) and hematologic criteria (n = 1